Lung cancer screening with helical computed tomography in older adult smokers: A decision and cost-effectiveness analysis

Journal of the American Medical Association

Volumn 289, Issue 3, 2003, Pages 313-322

  Mahadevia, Parthiv J ^a,e   Fleisher, Lee A ^a,c   Frick, Kevin D ^c   Eng, John ^a   Goodman, Steven N ^b,c   Powe, Neil R ^a,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins Bloomberg School of Public Health ^*

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY; ARTICLE; CANCER MORTALITY; CANCER SCREENING; COHORT ANALYSIS; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 0037438998     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.3.313     Document Type: Article

References (52)

1. Lerner B. Screening for cancer: a downside. New York Times. March 5, 2002:D6.
2. Kolata G. Lung cancer test is much in demand, but benefit is murky. New York Times. June 21, 2001: A1-A14.
3. Brice J. Low-dose CT: the promise and the paradox of lung cancer screening. Diagn Imaging (San Franc). 2000;22(5):44-53.
4. Lee TH, Brennan TA. Direct-to-consumer marketing of high-technology screening tests. N Engl J Med. 2002;346:529-531.
5. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75(suppl 1):191-202.
6. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. J Occup Med. 1986;28:746-750.
7. Tockman MS. Survival and mortality from lung cancer in a screened population: the Johns Hopkins study. Chest 1986;89(suppl 4):324S-326S.
8. Melamed MR, Flehinger BJ, Zaman MB. Impact of early detection on the clinical course of lung cancer. Surg Clin North Am. 1987;67:909-924.
9. Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer. 1990; 45:26-33.
10. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer: a critique of the Mayo Lung Project. Cancer. 1991;67(suppl 4):1155-1164.
11. Hulka BS. Screening for cancer: lessons learned. J Occup Med. 1986;28:687-691.
12. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354: 99-105.
13. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project: initial findings on repeat screenings. Cancer. 2001;92:153-159.
14. Sone S, Li F, Yang ZG, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer. 2001;84:25-32.
15. Swensen SJ, Jett JR, Sloan JA, et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med. 2002;165:508-513.
16. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet. 1998;351:1242-1245.
17. Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol. 2002;20:911-920.
18. Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000;343:1627-1633.
19. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology. 1996;201:798-802.
20. Henschke CI, Yankelevitz DF. CT screening for lung cancer. Radiol Clin North Am. 2000;38:487-495.
21. Patz EF Jr, Rossi S, Harpole DH Jr, Herndon JE, Goodman PC. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest. 2000;117:1568-1571.
22. National Cancer Institute and the American Cancer Society. Early Lung Cancer Screening Workshop. March 7-8, 2001; Rockville, Md.
23. National Institutes of Health, National Cancer Institute. Fifty thousand current and former smokers needed for National Lung Screening Trial [press release]. September 18, 2002. Available at: http://www.nih.gov/news/pr/sep2002/nci-19a.htm. Accessibility verified December 18, 2002.
24. Spiral CT screens raise scientific, economic issues. Oncol News Int. 2000;9:1-30.
25. Kolata G. Questions grow over usefulness of some routine cancer tests. New York Times. December 30, 2001:A1-A16.
26. Grannis F Jr. Lung cancer screening: who will pick up the tab? Chest. 2002;121:1388-1390.
27. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1998) [database on CD-ROM]. Bethesda, Md: National Cancer Institute; 2001.
28. DevCan: Probability of Developing or Dying of Cancer [computer program]. Bethesda, Md: National Cancer Institute; 2001.
29. DeCamp MM Jr, Jaklitsch MT, Mentzer SJ, Harpole DH Jr, Sugarbaker DJ. The safety and versatility of video-thoracoscopy: a prospective analysis of 895 consecutive cases. J Am Coll Surg. 1995;181:113-120.
30. Jaklitsch MT, DeCamp MM Jr, Liptay MJ, et al. Video-assisted thoracic surgery in the elderly: a review of 307 cases. Chest. 1996;110:751-758
31. Celik M, Halezeroglu S, Senol C, et al. Video-assisted thoracoscopic surgery: experience with 341 cases. Eur J Cardiothorac Surg. 1998;14:113-116.
32. Shah SS, Tsang V, Goldstraw P. Open lung biopsy: a safe, reliable, and accurate method for diagnosis in diffuse lung disease. Respiration. 1992;59: 243-246.
33. Sagel SS, Ferguson TB, Forrest JV, Roper CL, Weldon CS, Clark RE. Percutaneous transthoracic aspiration needle biopsy. Ann Thorac Surg. 1978;26:399-405.
34. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med. 2001;345:181-188.
35. Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics. 2001;19:855-863.
36. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-3317.
37. American Medical Association. 1998 National Physician Fee Schedule Relative Value File. Chicago, III: American Medical Association; 1998.
38. Thomson Healthcare. Red Book: Drug Topics 2001. Montvale, NJ: Medical Economics Co Inc; 2001.
39. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997;18:51-76.
40. National Alliance for Caregiving (NAC), American Association of Retired Persons (AARP). Caregiving in the United States: Findings From a National Survey. Bethesda, Md and Washington, DC: NAC/AARP; 2001.
41. Hillner BE, Smith TJ. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer. Semin Oncol. 1996;23 (suppl 2 pt 5):25-30.
42. Gurley MB, Richli WR, Waugh KA. Outpatient management of pneumothorax after fine-needle aspiration: economic advantages for the hospital and patient. Radiology. 1998;209:717-722.
43. Data Pro [computer program]. Version 6.0. Boston, Mass: TreeAge Inc; 2002.
44. Burns DM. Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. Cancer. 2000;89(suppl 11):2506-2509.
45. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000; 321:323-329.
46. Eddy DM. Screening for lung cancer. Ann Intern Med. 1990;112:73-74.
47. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer: results of the Memorial Sloan-Kettering study in New York. Chest. 1984;86:44-53.
48. Walter SD, Kubik A, Parkin DM, Reissigova J, Adamec M, Khlat M. The natural history of lung cancer estimated from the results of a randomized trial of screening. Cancer Causes Control. 1992;3:115-123.
49. Dolan P. Modeling valuations for EuroQoL health states. Med Care. 1997;35:1095-1108.
50. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;60: 5954-5958.
51. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20 (suppl 3):21-35.
52. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999;86:1867-1876.